共 138 条
[11]
Bernstein HG(2018)Statistically significant antidepressant-placebo differences on subjective symptom-rating scales do not prove that the drugs work: effect size and method bias matter! Front Psychiatry 9 517-2686
[12]
Steiner J(1995)Adjunctive treatments in schizophrenia: pharmacotherapies and electroconvulsive therapy Schizophr Bull 21 607-68
[13]
Bogerts B(2018)Venous thromboembolism during treatment with antipsychotics: a review of current evidence CNS Drugs 32 47-124
[14]
Braun K(2002)Inhibition by theanine of binding of [3H] AMPA,[3H] kainate, and [3H] MDL 105,519 to glutamate receptors Biosci Biotechnol Biochem 66 2683-276
[15]
Jankowski Z(2017)Comparison of saffron versus fluoxetine in treatment of mild to moderate postpartum depression: a double-blind, randomized clinical trial Pharmacopsychiatry 50 64-155
[16]
Kumaratilake J(2018)Neurobiological effects of theanine and its possible use in neurology and psychiatry Zh Nevrol Psikhiatr Im S S Korsakova 118 118-1910
[17]
Henneberg M(1987)The positive and negative syndrome scale (PANSS) for schizophrenia Schizophr Bull 13 261-62
[18]
Gos T(2014)Raloxifene adjunctive therapy for postmenopausal women suffering from chronic schizophrenia: a randomized double-blind and placebo controlled trial DARU J Pharmaceutical Sci 22 55-296
[19]
Chouinard G(2013)Calculating and reporting effect sizes to facilitate cumulative science: a practical primer for t-tests and ANOVAs Front Psychol 4 863-97
[20]
Margolese HC(2014)Neurobiological effects of the green tea constituent theanine and its potential role in the treatment of psychiatric and neurodegenerative disorders Nutr Neurosci 17 145-1466